about
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesisIs ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigationTopotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.Incorporation of pazopanib in maintenance therapy of ovarian cancer.Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG).From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples.Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall SurvivalCurrent knowledge and open issues regarding bevacizumab in gynaecological neoplasms.Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.A miRNA signature assessing ovarian cancer prognosis.Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study.Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy.Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)
P50
Q30250038-BF471A74-214D-4499-B5F8-9949BC25E02AQ30540674-4015CA9C-FDAB-4F61-A74D-E1C3ED08A0D8Q31138109-C4BFBC6A-DF1B-4057-B9C5-A5A080AE0F04Q33361491-291D84A7-E6C0-4240-B3F9-32AB0AB89296Q33372127-2CA06AFC-4F24-48D1-8274-70B871F80C07Q33410174-BBC7207E-C242-4606-8722-C3A80A97A5C1Q33413609-B62A5EED-C297-4B8C-A136-E5F6213EB71DQ33417673-0C9F2716-2248-4F91-A280-3BF8F7CF3B62Q33427744-69DCCEEA-C1D4-491B-A5C7-1CD4839B4898Q33433804-8561E389-F5A7-4B9C-9FE9-3AB9B5715962Q33772333-3D33071E-089F-4712-A414-A71C5503ACD1Q33845165-0EC3B871-29F2-4D20-9F9F-66890BE13669Q36859124-FEE87A35-39F4-4382-B57A-AAAAB91067AEQ36909750-B709CB16-53CD-42B0-B6F2-FC6D236FC9C3Q37953105-D8AC5DED-5314-4E09-9A8D-1A9D9F01E7C9Q38639556-EE3ECE06-472C-4418-8910-E103C0988F18Q42330446-6DE61C3F-1F24-40CF-84CC-B9C687DDE1F9Q42375254-1CC800A3-D2AC-42D8-8BE4-9972DB9099B5Q44318064-11E5C75C-9505-4EFB-B0E6-4D179C45A411Q45178810-021B5D1D-8FB4-428C-98A4-C16796B7608DQ46748103-B08C8E67-BC6A-46A9-8904-9FE0C0B95B0FQ50564383-FAFCE4FC-21A2-4A27-84B1-1652F0C8BCB1Q50909597-ABBC6D92-6E3F-4FEE-B099-EDCCF89DEDBFQ53973824-B51C556E-C33A-4DC2-9FD0-60B50E8854CAQ56358229-1F4BD274-1C0B-4192-81C9-61B6B943BE81
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sandro Pignata
@ast
Sandro Pignata
@en
Sandro Pignata
@es
Sandro Pignata
@nl
type
label
Sandro Pignata
@ast
Sandro Pignata
@en
Sandro Pignata
@es
Sandro Pignata
@nl
prefLabel
Sandro Pignata
@ast
Sandro Pignata
@en
Sandro Pignata
@es
Sandro Pignata
@nl
P106
P1153
7004271576
P21
P31
P496
0000-0002-8836-2633